SEC Form 4 · accession 0001209191-15-028978
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paul M Silva
Officer — SVP & Corp Controller
Period of report
Mar 23, 2015
Accepted (ET)
Mar 24, 2015 · 6:07 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 23, 2015 | S | 100 | $122.10 | D | 20,525 | D | |
| Common StockF2,F3 | Mar 23, 2015 | S | 750 | $125.05 | D | 19,775 | D | |
| Common StockF3,F4 | Mar 23, 2015 | S | 1,100 | $125.90 | D | 18,675 | D | |
| Common StockF3,F5 | Mar 23, 2015 | S | 300 | $127.45 | D | 18,375 | D | |
| Common Stock | holding | — | — | — | 169 | I | 401(k) |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $125.05 (range $124.57 to $125.32).
- F3Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $125.90 (range $125.64 to $126.41).
- F5Open market sales reported on this line occurred at a weighted average price of $127.45 (range $127.10 to $128.04).